Davis Polk advised the joint book-running managers in connection with a $115.1 million SEC-registered offering of 5,479,750 ordinary shares of Theravance Biopharma, Inc. The ordinary shares are listed on the NASDAQ Global Market under the symbol “TBPH.”

Headquartered in South San Francisco, California, Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that make a difference in the lives of patients suffering from serious illness, primarily for use in the acute care setting.

The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jeffrey Gould and associate Randy Li. The tax team included partner Rachel D. Kleinberg and associate Lena X. Qiu. Associate Michelle Gross provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post